Your browser doesn't support javascript.
loading
Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury.
Takahashi, Masaki; Wada, Takeshi; Nakae, Ryuta; Fujiki, Yu; Kanaya, Takahiro; Takayama, Yasuhiro; Suzuki, Go; Naoe, Yasutaka; Yokobori, Shoji.
Affiliation
  • Takahashi M; Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
  • Wada T; Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
  • Nakae R; Department of Emergency and Critical Care Medicine, Nippon Medical School Hospital, Tokyo, Japan.
  • Fujiki Y; Emergency and Critical Care Center, Kawaguchi Municipal Medical Center, Saitama, Japan.
  • Kanaya T; Department of Emergency and Critical Care Medicine, Nippon Medical School Hospital, Tokyo, Japan.
  • Takayama Y; Department of Emergency and Critical Care Medicine, Nippon Medical School Hospital, Tokyo, Japan.
  • Suzuki G; Emergency and Critical Care Center, Kawaguchi Municipal Medical Center, Saitama, Japan.
  • Naoe Y; Emergency and Critical Care Center, Kawaguchi Municipal Medical Center, Saitama, Japan.
  • Yokobori S; Department of Emergency and Critical Care Medicine, Nippon Medical School Hospital, Tokyo, Japan.
Front Immunol ; 13: 981826, 2022.
Article in En | MEDLINE | ID: mdl-36248813
Coagulopathy management is an important strategy for preventing secondary brain damage in patients with traumatic brain injury (TBI). Antithrombin (AT) is a natural anticoagulant that controls coagulation and inflammation pathways. However, the significance of AT activity levels for outcomes in patients with trauma remains unclear. This study aimed to investigate the relationship between AT activity levels and long-term outcomes in patients with TBI; this was a sub-analysis of a prior study that collected blood samples of trauma patients prospectively in a tertiary care center in Kawaguchi City, Japan. We included patients with isolated TBI (iTBI) aged ≥16 years admitted directly to our hospital within 1 h after injury between April 2018 and March 2021. General coagulofibrinolytic and specific molecular biomarkers, including AT, were measured at 1, 3, 6, 12, and 24 h after injury. We analyzed changes in the AT activity levels during the study period and the impact of the AT activity levels on long-term outcomes, the Glasgow Outcome Scale-Extended (GOSE), 6 months after injury. 49 patients were included in this study; 24 had good neurological outcomes (GOSE 6-8), and 25 had poor neurological outcomes (GOSE 1-5). Low AT activity levels were shown within 1 h after injury in patients in the poor GOSE group; this was associated with poor outcomes. Furthermore, AT activity levels 1 h after injury had a strong predictive value for long-term outcomes (area under the receiver operating characteristic curve of 0.871; 95% CI: 0.747-0.994). Multivariate logistic regression analysis with various biomarkers showed that AT was an independent factor of long-term outcome (adjusted odds ratio: 0.873; 95% CI: 0.765-0.996; p=0.043). Another multivariate analysis with severity scores showed that low AT activity levels were associated with poor outcomes (adjusted odds ratio: 0.909; 95% CI: 0.822-1.010; p=0.063). We demonstrated that the AT activity level soon after injury could be a predictor of long-term neurological prognosis in patients with iTBI.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antithrombins / Brain Injuries, Traumatic Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Japón Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antithrombins / Brain Injuries, Traumatic Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Japón Country of publication: Suiza